AlphaMadera's AlphaVal page computes IRadimed Corporation's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag IRMD as undervalued, fairly valued, or overvalued.

What is IRadimed Corporation's fair value?

Fair value for IRMD is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value IRMD?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from IRMD's most recent reported fundamentals.

IRMD - IRadimed Corporation

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $120.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Strong

Trading 74.0% above fair value

Current Price $95.69

Bear Case $32.50 66.0% downside ($32.50 - $95.69) / $95.69 = -66.0% 12% stage 1 growth, 11% discount

Fair Value $54.98 42.5% downside ($54.98 - $95.69) / $95.69 = -42.5% 19% stage 1 growth, 11% discount

Bull Case $82.78 13.5% downside ($82.78 - $95.69) / $95.69 = -13.5% 25% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

19.3%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (19% base case)

Terminal Value % of EV 46%

Implied Market Multiple 78.2x

Market is pricing in (growth) 27.2% vs our 19.3% base

Plain-Language Summary

Using a two-stage FCF DCF with 19% growth decelerating over 15 years, discounted at 11%, the base-case intrinsic value is $54.98 per share.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions